⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Finnadvance and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Finnadvance
↗Oulu, Finland
Finnadvance Oy is a privately held Finnish biotechnology and microtechnology company developing AKITA-branded organ-on-chip and microphysiological-system platforms. Its products combine microfluidics, biomaterials, microfabrication, perfusion, mechanobiology and integrated measurements to create more physiologically relevant 3D cell, tissue, organ and biological-barrier models for preclinical drug research, toxicology, disease modeling and personalized medicine. The company positions AKITA as a higher-throughput alternative or complement to conventional 2D cell culture and some animal-testing workflows. ([akita.bio](https://akita.bio/company))
The company operates from Oulu for engineering and production and maintains a Helsinki office presence. Its platform portfolio includes AKITA microfluidic plates, lids and flow systems, TEER and impedance-related measurement capabilities, organoid-compatible culture systems, barrier models and custom chip-design/fabrication services. Publicly disclosed applications include blood-brain-barrier, lung, skin, gut, neural, cancer, cornea and inflammatory-tissue models. Finnadvance is a platform and research-tools company rather than a conventional drug developer; no proprietary therapeutic drug pipeline was identified. ([businessfinland.fi](https://www.businessfinland.fi/4b04f5/globalassets/health/bf_jointoffering_cancerexpertise.pdf?utm_source=openai))
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Organ-on-chip platforms, microphysiological systems and preclinical research technology
SIZE & FINANCIALS
Employees:1-50
Revenue:Unknown; publicly described as pre-revenue in an earlier startup profile, although the company now reports commercial product shipments and paid pilots
Founded:2018
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:Approximately €1.75M disclosed equity/seed funding, plus approximately €1.6M in EU grants; exact cumulative funding is not publicly reconciled
Investors:Athensmed, Voima Ventures, Icebreaker.vc, Takoa Invest, Sauli Törmälä, Leena Niemistö, European Union funding programs, Business Finland, ELY Centre / Finnish regional development funding
PIPELINE
Stage:Commercial
Lead Drug Stage:Not applicable; Finnadvance has no identified proprietary therapeutic drug candidate. Its most advanced assets are commercial AKITA organ-on-chip platforms and multi-organ systems.
Modalities:Organ-on-chip, Microphysiological systems, Microfluidic cell culture, 3D cell culture, Organoids and spheroids, Disease-on-chip, Biomimetic culture surfaces, Biologic scaffolds, TEER and impedance measurement, Perfusion and mechanobiology, Silicon, PDMS and polymer microfabrication, Automation-compatible laboratory hardware, Research software and data-analysis tooling
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Experimentica — commercial partnership for cornea-on-chip development and ophthalmic drug-testing applications. ([linkedin.com](https://www.linkedin.com/company/akitabio/?utm_source=openai)), University of Oulu — scientific and technology collaboration involving microfluidics, biomaterials, cell biology and organ-on-chip validation. ([oulu.fi](https://www.oulu.fi/fi/yliopisto/tiedekunnat-ja-yksikot/biokemian-ja-molekyylilaaketieteen-tiedekunta/alumnitarinat?utm_source=openai)), University of Eastern Finland — collaboration on neuron-on-chip, blood-brain-barrier and neuroinflammation research. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35163293/?utm_source=openai)), University of Helsinki — collaboration through the Drug Research Program and pharmaceutical research facilities. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38346163/?utm_source=openai)), University of Luxembourg / Luxembourg Centre for Systems Biomedicine — collaboration on brain and biological-barrier models. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38346163/?utm_source=openai)), Organo-Therapeutics — collaboration referenced in AKITA publication materials involving biological-barrier and organ-on-chip research. ([akita.bio](https://akita.bio/resources)), AstraZeneca and the NAP4DIVE consortium — Finnadvance contributes to blood-brain-barrier-on-chip platform development in a European research consortium. ([nap4dive.eu](https://nap4dive.eu/who-we-are/?utm_source=openai)), Korea Institute of Science and Technology and Asian research partners — collaboration and conference activity around automation-compatible organ-on-chip systems. ([termis.cjint.kr](https://termis.cjint.kr/download/TERMIS-AP%202022_programbook_compressed.pdf?utm_source=openai)), MenoBrain consortium — EU Marie Skłodowska-Curie doctoral network involving Finnadvance, Universitätsklinikum Jena, Leiden University, Uppsala University, INSERM and Fundación Pasqual Maragall. ([linkedin.com](https://www.linkedin.com/company/akitabio/?utm_source=openai))
COMPETITION
Position:Emerging
Competitors:MIMETAS, Emulate, CN Bio, InSphero, TissUse, Hesperos, Nortis, Kirkstall +4 more
LEADERSHIP
Key Executives:
Prateek Singh - Founder and Chief Executive Officer
Hoang-Tuan Nguyen - Chief Technology Officer
Jari Moilanen - Chief Operating Officer
Sébastien Mosser - Chief Scientific Officer
Scientific Founders:Prateek Singh — founder and CEO, Minna Kihlström — early Finnadvance scientific team member and inventor, Tuomas Nurmi — early Finnadvance scientific and engineering team member and inventor, Hoang-Tuan Nguyen — CTO and key platform inventor
LINKS
Website:finnadvance.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Finnadvance. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.